IDRA

Idera Pharmaceuticals, Inc. [IDRA] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

IDRA Stock Summary

In the News

IDRA Financial details

Company Rating
-
Market Cap
0
Income
-41.05M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
13
Optionable
No
Shortable
Yes
Earnings
29 Mar 2023
P/E
-88.68
Forward P/E
-
PEG
7.9
P/S
-
P/B
140.4
P/C
-
P/FCF
-
Quick Ratio
0.24
Current Ratio
0.32
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-6.01
EPS next Y
-
EPS next Q
-
EPS this Y
-114.56%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-28.44%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-99.91%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-45%
ROE
-194%
ROC
-0.7%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.4201-16.0
52W High
-
52W Low
-
RSI
-
Rel Volume
10.93
Avg Volume
34.02K
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
-
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-

Something similar

Top by Market Cap
VTI
AMZN
ABEA.DE
FXAIX
3V64.DE
Same Sector
MBRX
PETVW
PETV
2181.HK
KALA
Check Those
BAND
BRC
6732.TWO
9728.T
000633.SZ
Similar Market Cap
AVADHSUGAR.NS
NSCI.L
LFTRU
NSH-UN
000155.SZ

Company Profile

Healthcare Biotechnology
  • Volume Average 34.02K
  • Employee 13
  • CEO Mr. Vincent J. Milano
  • Headquarters Exton,PA,US
  • IPO Date 1996-01-25
  • Website https://www.iderapharma.com

Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration agreement with Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.